Laguna is an international, clinical-stage biotechnology company driving a paradigm shift in oncology by unlocking the untapped therapeutic power of innate T cells. Operating with an exceptionally capital-efficient, global model, we have developed proprietary platforms including our lead QUAIL platform, and our next-gen cancer-targeting IBIS platform that utilize precisely engineered, highly attenuated pathogens to safely trigger a massive in vivo expansion and activation of γδ T cells. By orchestrating a durable, systems-level immune response directly inside the patient, we overcome the prohibitive costs of ex vivo cell engineering and the terminal exhaustion caused by existing small molecules. Entering the clinic this year to treat high-risk Acute Myeloid Leukemia (AML), Laguna is positioned to rapidly expand its pipeline into multiple myeloma, sarcomas, and notoriously difficult solid tumors, such as MSS CRC, efficiently weaponizing the innate immune system to cure cancers that have historically evaded modern therapies.
